A Phase I/II Dose Escalation/Adaptive Design Study to Evaluate the Safety and Efficacy of IMCY-0141 in Patients With Relapsing Remitting-Multiple Sclerosis (RR-MS)
Latest Information Update: 14 Mar 2024
At a glance
- Drugs IMCY-0141 (Primary) ; Dimethyl fumarate
- Indications Multiple sclerosis
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms ISEMIS Study
- Sponsors ImCyse
- 07 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 19 Apr 2022 New trial record
- 13 Apr 2022 According to Imcyse media release, first patient has been dosed in this trial;